stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) Book value per share
Zai Lab Limited Unsponsored ADR's book value per share at the end of fiscal 2025 was 6.5×, down 23.1% from 8.5× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 0.0×. Over the past ten years it has ranged from −5.5× (fiscal 2016) to 15.1× (fiscal 2020); the current reading is higher than 45% of that period. Zai Lab Limited Unsponsored ADR ranks 477th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 6.5× | (23.13%) |
| FY2024 | 8.5× | 3.16% |
| FY2023 | 8.2× | (24.52%) |
| FY2022 | 10.9× | (26.46%) |
| FY2021 | 14.8× | (1.44%) |
| FY2020 | 15.1× | 228.89% |
| FY2019 | 4.6× | (4.08%) |
| FY2018 | 4.8× | (55.86%) |
| FY2017 | 10.8× | — |
| FY2016 | −5.5× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 5.4× | (9.09%) |
| Mar 2026 | 6.0× | (8.49%) |
| Dec 2025 | 6.5× | (5.27%) |
| 32 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| CLDX Celldex Therapeutics, Inc. compare | 9.2× |
| MBX MBX Biosciences, Inc. compare | 8.6× |
| XNCR Xencor, Inc. compare | 6.6× |
| PHVS Pharvaris N.V. compare | 5.1× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 5.1× |
| RCUS Arcus Biosciences, Inc. compare | 2.8× |
| ADMA ADMA Biologics Inc compare | 2.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 1.7× |
| ZLAB Zai Lab Limited Unsponsored ADR | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on ZLAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement